Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C46H73N4O9 |
| Molecular Weight | 826.0932 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=[N+](CC)C=CC=C2)C(=O)C3=CC=CC=C3OC)OC
InChI
InChIKey=HGOAIWZFTWACBD-RRHRGVEJSA-O
InChI=1S/C46H72N4O9/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3/p+1/t40-/m1/s1
| Molecular Formula | C46H73N4O9 |
| Molecular Weight | 826.0932 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL250 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1663352 |
0.27 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of a platelet-activating factor receptor antagonist, E5880, on cerebral vasospasm after aneurysmal subarachnoid hemorrhage--open clinical trial to investigate efficacy and safety. | 2001-04 |
|
| Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures. | 1997-04-18 |
|
| Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models. | 1991-07 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11381675
Intravenous Minopafant administration (300 ug or 1200 ug twice daily) was begun within 4 days and continued for 14 days.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9134961
Curator's Comment: The cultured neurons were exposed to glutamate (1 mM) for 60 min. Twenty-four hours after this exposure, protective effect of E5880 against neuronal damage was tested.
Minopafant (E5880) was tested for its neuroprotective activity in primary neuronal cultures isolated from embryonic rat cerebral cortex. Protective effect was observed in cultures treated with E5880 (P < 0.01 at 10 nM E5880)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 16:58:13 GMT 2025
by
admin
on
Wed Apr 02 16:58:13 GMT 2025
|
| Record UNII |
R382T79GF8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
130991
Created by
admin on Wed Apr 02 16:58:13 GMT 2025 , Edited by admin on Wed Apr 02 16:58:13 GMT 2025
|
PRIMARY | |||
|
R382T79GF8
Created by
admin on Wed Apr 02 16:58:13 GMT 2025 , Edited by admin on Wed Apr 02 16:58:13 GMT 2025
|
PRIMARY | |||
|
760911-49-7
Created by
admin on Wed Apr 02 16:58:13 GMT 2025 , Edited by admin on Wed Apr 02 16:58:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TARGET -> INHIBITOR |
|
||
|
IONIC MOIETY |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|